| Expression pattern: |
DN |
| Associated gene: |
PTEN, AKT, pAKT |
| Associated microRNA: |
miR-1305 |
| Biological function: |
inhibits cell growth and proliferation; promotes apoptosis; attenuates malignant cellular processes |
| Molecular mechanism: |
Acts as a miRNA sponge for miR-1305 to upregulate PTEN and suppress AKT phosphorylation. |
| Biological pathway or process: |
PI3K/AKT (inhibits); apoptosis (promotes); proliferation (inhibits); ceRNA regulation (other) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; Luciferase Reporter Assay; Transfection; MTT; Colony Formation Assay; Annexin V/PI Flow Cytometry; Cell Cycle Assay; Western Blot; Clinical Sample Validation; ROC Analysis; Bioinformatics Analysis |
| Clinical significance: |
Downregulation correlated with clinicopathological characteristics and circLIFRSA may serve as an early diagnostic biomarker (blood-based) for NSCLC, with ROC AUC 0.8578 distinguishing benign lung diseases from lung cancer. |
| Description: |
circLIFRSA (hsa_circ_0072298), derived from LIFRSA, is down-regulated in NSCLC tissues and cell lines and mainly localizes to the cytoplasm. It suppresses malignant phenotypes by sponging miR-1305 to relieve repression of PTEN, thereby reducing AKT phosphorylation, inhibiting growth/proliferation and promoting apoptosis. Blood circLIFRSA shows diagnostic potential for distinguishing lung cancer/NSCLC from benign lung disease. |
| Confidence score: |
0.8252 |